Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia

Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia

Definition and Scope of Pharmacovigilance

Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems. In Saudi Arabia, the framework for pharmacovigilance has matured significantly, aligning with global standards established by the International Council for Harmonisation (ICH) and the WHO. The primary objectives of pharmacovigilance are to protect public health, optimize the benefit-risk ratio of medicines, and foster clinical safety awareness among healthcare providers and patients.

Key Safety Definitions

Understanding the precise terminology of drug safety is critical for correct reporting and clinical monitoring:

• Adverse Drug Reaction (ADR): A response to a drug which is noxious and unintended, occurring at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease. An ADR implies a causal relationship between the drug and the event.
• Adverse Drug Event (ADE): Any untoward medical occurrence that may appear during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with the treatment. An ADE covers injuries caused by medication use, including ADRs, overdoses, and medication errors.
• Medication Error: Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare professional, patient, or consumer.
• Side Effect: An expected, well-known, and dose-dependent effect of a drug that is not the primary therapeutic objective (e.g., sedation with first-generation antihistamines).

The Rawlins-Thompson Classification of ADRs

ADRs are classified into six distinct types using the Rawlins-Thompson criteria, which guide clinical management and reporting:

• Type A (Augmented): Predictable, dose-dependent reactions that are extensions of the drug's known pharmacological profile (e.g., hypoglycemia from insulin, bleeding from warfarin). They account for over 80% of all ADRs and are managed by dose adjustment.
• Type B (Bizarre): Unpredictable, dose-independent, idiosyncratic, or immunologically mediated reactions (e.g., anaphylaxis from penicillin, Stevens-Johnson syndrome from carbamazepine). They carry high mortality and require immediate drug discontinuation.
• Type C (Chronic): Occur as a result of long-term therapy and accumulation (e.g., adrenal suppression from chronic corticosteroids).
• Type D (Delayed): Lag behind exposure and occur long after drug use (e.g., teratogenic effects or carcinogenesis).
• Type E (End-of-use): Occur upon withdrawal of the drug (e.g., rebound hypertension with clonidine).
• Type F (Failure of therapy): Unexpected failure of a drug to produce therapeutic effect, often due to drug interactions, poor quality, or tolerance.

Causality Assessment and the Naranjo Algorithm

When a suspected ADR is identified, clinicians must perform a causality assessment to evaluate the strength of the association. The most widely used tool is the Naranjo Algorithm (ADR Probability Scale). This questionnaire consists of 10 structured questions regarding timing, previous reports, dechallenge, rechallenge, and alternative causes. Responses are scored to classify the reaction:

• Score $\ge 9$: Definite (the adverse event followed a reasonable temporal sequence, was confirmed by withdrawal and rechallenge, and cannot be explained by disease progression).
• Score 5–8: Probable (reasonable temporal sequence, confirmed by dechallenge or clinical recovery, alternative explanations unlikely).
• Score 1–4: Possible (temporal sequence is reasonable, but alternative explanations or co-administered drugs are possible).
• Score $\le 0$: Doubtful (likely explained by other factors).

The Saudi Food and Drug Authority (SFDA) and NPC

The Saudi Food and Drug Authority (SFDA) regulates the safety, quality, efficacy, and marketing authorizations of pharmaceuticals in Saudi Arabia. Within the SFDA, the National Pharmacovigilance and Drug Safety Center (NPC) acts as the central national authority responsible for:

• Collecting, evaluating, and archiving ADR reports.
• Conducting signal detection using advanced statistics (e.g., reporting odds ratio) to identify new, previously unrecognized safety risks.
• Implementing Risk Minimization Measures (RMMs), such as specialized pregnancy prevention programs for teratogenic medications like isotretinoin.
• Issuing national drug safety alerts, recalls, and updates to product monographs.
• Collaborating with the WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre).

The Saudi Vigilance System and Reporting Guidelines

Healthcare facilities and pharmaceutical manufacturers are legally mandated to report safety concerns to the SFDA NPC. The Saudi Vigilance System is the national portal through which reports are submitted.

• Individual Case Safety Reports (ICSRs): The basic unit of safety reporting, containing four minimum criteria to be valid: an identifiable patient, an identifiable reporter, a suspect drug product, and a suspect adverse reaction.
• Pharmacist's Role: Pharmacists are the primary reporters of ADRs in hospital settings. They coordinate with institutional Pharmacy and Therapeutics (P&T) committees and Patient Safety departments to monitor safety and configure electronic health record alerts to prompt reporting. Reports can also be submitted directly via the SFDA mobile application.
• Reporting Timelines:
  • Serious Adverse Reactions (resulting in death, life-threatening events, hospitalization, congenital anomaly, or permanent disability): Must be reported within 15 calendar days of discovery.
  • Non-serious Adverse Reactions: Must be reported within 90 calendar days.

ADR Classification Reference Table